SavedAdd your journal

Journals / Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi / 2023 / Cilt: 12 Sayı: 3

A Meta-analysis on the Efficacy of Various Medicated Treatment Options for Osteoporosis

Osteoporoz için Çeşitli İlaçlı Tedavi Seçeneklerinin Etkinliği Üzerine Bir Meta-analiz

Nurmuhammet TAŞ
Pages
1131–1140
Publication Date
2023-09-26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our findings show that osteoporosis drugs have an overall effect on these parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This meta-analysis aims to review and evaluate different osteoporosis treatment options and examine their efficacy.
📊
Key Findings & Data:The study aimed to evaluate the effect of osteoporosis drugs on serum phosphate, sCTX, and serum 25(OH)D values.
💡
Conclusion & Impact:Our findings show that osteoporosis drugs have an overall effect on these parameters.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Bifosfonat · D Vitamini · Odanacatib

Abstract

This meta-analysis aims to review and evaluate different osteoporosis treatment options and examine their efficacy. In particular, the effectiveness of vitamin D, bisphosphonates, odanacatib, neridronate, teriparatide, and raloxifene in the treatment of osteoporosis is investigated. For this purpose, the meta-analysis method, which allows the existing studies to be collated and interpreted, was used. Ten primary studies were included in the study. The study aimed to evaluate the effect of osteoporosis drugs on serum phosphate, sCTX, and serum 25(OH)D values. Our findings show that osteoporosis drugs have an overall effect on these parameters. The pooled effect size of osteoporosis drugs was calculated as-1.53 (CI: -3,00 to -0,07). Separate analyses for serum phosphate, sCTX, and serum 25(OH)D values also showed positive effects of these drugs.

Özet

Bu meta-analizin amacı, osteoporoz için farklı tedavi seçeneklerini gözden geçirmek ve değerlendirmek, etkinliklerini incelemektir. Özellikle, osteoporoz tedavisinde D vitamini, bifosfonatlar, odanacatib, neridronat, teriparatid ve raloksifenin kullanımının tedavi sürecindeki etkinliği araştırılmaktadır. Bu amaçla mevcut araştırmaların harmanlanarak yorumlanmasına olanak sunan meta-analiz yöntemi kullanılmıştır. Çalışmaya 10 birincil çalışma dâhil edilmiştir. Çalışma, osteoporoz ilaçlarının serum phosphate, sCTX ve Serum 25(OH)D değerleri üzerindeki etkisini değerlendirmeyi amaçlamıştır. Bulgularımız, osteoporoz ilaçlarının bu parametreler üzerinde genel bir etkiye sahip olduğunu göstermektedir. Osteoporoz ilaçlarının birleştirilmiş etki büyüklüğü -1,53 (CI: -3,00 ila -0,07) olarak hesaplanmıştır. Serum phosphate, sCTX ve Serum 25(OH)D değerleri için ayrı ayrı yapılan analizlerde de bu ilaçların olumlu etkileri tespit edilmiştir.

🔖

Cite This Article

TAŞ, N. (2023). A Meta-analysis on the Efficacy of Various Medicated Treatment Options for Osteoporosis. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 Sayı: 3, 1131–1140. https://ajindex.com/articles/962852

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Tu, K. N, Lie, J. D, Wan, C. K. V, Cameron, M, Austel, A. G, Nguyen, J. K. and Hyun, D. (2018). “Osteoporosis: a Review of Treatment Options”. Pharmacy and Therapeutics, 43(2), 92-104
  2. Hopkins, R. B, Goeree, R, Pullenayegum, E, Adachi, J. D, Papaioannou, A, Xie, F. and Thabane, L. (2011). “The Relative Efficacy of Nine Osteoporosis Medications for Reducing the Rate of Fractures in Post-Menopausal Women”. BMC Musculoskeletal Disorders, 12, 1-16
  3. Srivastava, A. K, Vliet, E. L, Michael Lewiecki, E, Maricic, M, Abdelmalek, A, Gluck, O. and Baylink, D. J. (2005). “Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis”. Current Medical Research and Opinion, 21(7), 1015-1026
  4. Rossini, M, Gatti, D, Viapiana, O, Fracassi, E, Idolazzi, L, Zanoni, S. and Adami, S. (2012). “Short-term Effects on Bone Turnover Markers of a Single High Dose of Oral Vitamin D3”. The Journal of Clinical Endocrinology & Metabolism, 97(4), E622-E626. 5. van der Burgh, A. C, de Keyser, C. E, Zillikens, M. C. and Stricker, B. H. (2021). “The Effects of Osteoporotic and Non-Osteoporotic Medications on Fracture Risk and Bone Mineral Density”. Drugs, 81, 1831–1858.
  5. Chen, C. H, Lo, W. C, Hu, P. J, Chan, H. C, Shen, W. C, Wu, M. S. and Wu, M. Y. (2022). “Efficacy of Osteoporosis Medications for Patients with Chronic Kidney Disease: an Updated Systematic Review and Network Meta-Analysis”. Frontiers in Pharmacology, 13.
  6. Kan, B, Zhao, Q, Wang, L, Xue, S, Cai, H. and Yang, S. (2021). “Association Between Lipid Biomarkers and Osteoporosis: A Cross-Sectional Study. BMC Musculoskeletal Disorders”. 22(1), 759.
  7. Sabri, S. A, Chavarria, J. C, Ackert-Bicknell, C, Swanson, C. and Burger, E. (2023). “Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment”. Orthopedics, 46(1), e20-e26.
  8. Lin, S. Y, Hung, M. C, Chang, S. F, Tsuang, F. Y, Chang, J. Z. C. and Sun, J. S. (2021). “Efficacy and Safety of Postmenopausal Osteoporosis Treatments: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials”. Journal of Clinical Medicine, 10(14), 3043.
  9. Kendler, D. L, Cosman, F, Stad, R. K. and Ferrari, S. (2022). “Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review”. Advances in Therapy, 39(1), 58-74. 1